Benzinga

Benzinga

Benzinga

dimanche, août 23

Corcept Therapeutics Inc

CORTNASDAQ
Trade with Public
Trade with Public
$122.25
1.200.99%
À la clôture: Aug 21, 5:00 PM EST
$122.25
N/A
Après les heures: Aug 21, 4:00 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Corcept Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Corcept Therapeutics (CORT).

Price Target Range — 13 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Sell
Consensus RatingBuy# Analysts6Avg. Consensus PT$127Upside to Avg. PT+4.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 30, 2026Piper SandlerDavid AmsellemPT RaiseOverweight$88→$165
Jul 30, 2026Canaccord GenuityEdward NashPT RaiseBuy$150→$161
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.
Benzinga Newsdesk

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.
Avi Kapoor

PRO
Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target

Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved